Renaissance Capital logo

Processa Pharmaceuticals Priced, Nasdaq: PCSA

Developing an analog therapy for necrotic skin disease.

Industry: Health Care

First Day Return: n/a

Industry: Health Care

We are an emerging pharmaceutical company focused on the clinical development of drug products that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease), will begin developing a newly acquired drug once adequate funding is obtained, and are searching for additional products for our portfolio. On October 4, 2017, we acquired all the net assets of Promet Therapeutics, LLC (“Promet”), a private Delaware limited liability company, including the rights to the CoNCERT Agreement, in exchange for 4,535,035 shares of our common stock. Immediately following the transaction, the former equity holders of Promet owned approximately 84% and held approximately 6% of the shares for the benefit of CoNCERT in relation to the CoNCERT contribution of the license to Processa as part of the Section 351 transaction, and our stockholders immediately prior to the transaction owned approximately 10% of our common stock. Promet distributed 4,236,420 shares of the common stock it held to its partners. We traded on the OTC Pink Marketplace until December 8, 2018 when we listed our common stock on the OTCQB.
more less

Processa Pharmaceuticals (PCSA) Performance